Hoth Therapeutics (NASDAQ:HOTH) Releases Earnings Results, Misses Expectations By $0.01 EPS

Hoth Therapeutics (NASDAQ:HOTH) released its earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.01), Zacks reports.

Hoth Therapeutics Price Performance

HOTH stock traded down $0.05 during trading on Friday, reaching $0.80. 140,791 shares of the company were exchanged, compared to its average volume of 1,389,183. The company has a market capitalization of $5.52 million, a price-to-earnings ratio of -0.59 and a beta of 0.84. The company has a 50-day moving average of $0.92 and a two-hundred day moving average of $0.93. Hoth Therapeutics has a twelve month low of $0.58 and a twelve month high of $1.73.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HOTH shares. Benchmark reiterated a “speculative buy” rating and set a $3.00 price objective on shares of Hoth Therapeutics in a research note on Friday, October 11th. EF Hutton Acquisition Co. I raised shares of Hoth Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 21st. Finally, HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Hoth Therapeutics in a research note on Monday, November 4th.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.